secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001701541-23-000039
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics Q2 net loss $20M; cash $89.5M; BDTX-1535 shows initial clinical activity
--------------------------------------------------------------------------------

- Net loss $20.0M for Q2 2023 vs $23.2M for Q2 2022; R&D expenses $13.2M down from $16.2M.
- Cash, equivalents & investments $89.5M as of June 30, 2023; plus $75M gross from July follow-on offering extends runway into H1 2025.
- BDTX-1535 Phase 1 dose-escalation showed confirmed partial responses in 5 of 12 evaluable NSCLC patients; expansion cohorts initiated July 2023.
- Phase 1 trial for BDTX-4933 (BRAF/RAS inhibitor) initiated in Q2 2023; GBM dose-escalation update expected Q4 2023.
- FDA meeting planned in Q4 2023 to discuss accelerated approval pathway for BDTX-1535 in NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154123000039/0001701541-23-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154123000039/bdtx-20230811.htm
  HTML page:      https://secwatch.observer/filing/0001701541-23-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer